Core Points - Cyclacel Pharmaceuticals has regained compliance with Nasdaq Listing Rule 5550(a)(2) regarding the Minimum Bid Price Requirement as of June 3, 2025 [1][2] - The company had previously received a notification from Nasdaq on December 6, 2024, indicating non-compliance due to its shares trading below $1.00 for 30 consecutive business days [2] - Following the notification, Cyclacel's shares closed at or above $1.00 for 15 consecutive business days from May 12, 2025, to June 2, 2025, leading to the closure of the compliance matter [2] Company Overview - Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative cancer medicines based on cell cycle, transcriptional regulation, and mitosis biology [3] - The company's key program includes plogosertib, a PLK1 inhibitor targeting both solid tumors and hematological malignancies [3] - Cyclacel aims to build a diversified biopharmaceutical business with a pipeline of novel drug candidates addressing oncology and hematology indications [3]
CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT